Perspective Therapeutics (CATX) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Perspective Therapeutics (CATX) over the past year, losing 14.8% versus a loss of 29.8%. Over five years, CATX leads with a -56.3% price change compared with -58.3% for TLSI. Perspective Therapeutics is the larger company by market cap ($302.4 million vs $247.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | TLSI |
|---|---|---|
| Share price | $2.65 | $4.02 |
| Market cap | $302.36M | $247.53M |
| 1-day change | -2.26% | -2.66% |
| YTD return | -1.45% | -40.83% |
| 1-year return | -29.79% | -14.85% |
| 5-year return | -56.29% | -58.28% |
| EPS (TTM) | $-1.33 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $7.95 |
| 52-week low | $1.96 | $2.20 |
| Distance from 52-week high | -57.00% | -49.43% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +363.98% | +158.71% |
| Average volume | 1.67M | 275.38K |
| Shares outstanding | 114.15M | 61.57M |
| Employees | 163 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSI has outperformed CATX by 14.9 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
CATX vs TLSI FAQ
Which is bigger, Perspective Therapeutics or TriSalus Life Sciences?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $302.36M compared with $247.53M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, CATX or TLSI?
TLSI returned -14.85% over the past 12 months, compared with -29.79% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical Specialities for TriSalus Life Sciences.